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1. Introduction
Talking about Alzheimer’s disease (AD) on a biochemical level needs to highlight the molec‐
ular „corpus delicti“: the amyloid or senile plaques [1]. These plaques are extracellular fibrillar
deposits in the cortex and hippocampus mainly composed of a single proteinaceous com‐
pound, the Aβ peptide comprising predominantly 40 or 42 amino acid residues (Aβ40, Aβ42)
[2]. The Aβ peptides originate by sequential ectodomain shedding and regulated intramem‐
brane proteolysis (RIP) of the amyloid precursor protein (APP), a type I integral membrane
protein highly expressed in neurons including synaptic compartments. The responsible
proteases, the famous β- and γ-secretase respectively, have been reviewed in detail and will
not be part of this paper [3, 4]. Since the cloning of APP 25 years ago, more than 9,000 publi‐
cations (about one per day!) are listed for this protein in the PubMed database indicating its
pivotal position in the amyloid cascade hypothesis [5], which constitutes the widely accepted
pathogenic cascade ultimately leading to AD. While some years ago the plaques themselves
were thought to be the primary cause of disease, it is nowadays well recognized that soluble
Aβ oligomers are responsible for many of the neurotoxic properties causing memory dys‐
function and finally dementia.
Despite intense research efforts AD can so far only be insufficiently treated in a purely
symptomatic way and disease-modifying drugs are most wanted but are still not available [6].
In order to get a glimpse of understanding AD pathology at a biochemical level, we therefore
have to understand the molecular structure of the key-player APP and its connected protein
network. The structure, however, needs to be correlated with the physiological functions and
the deregulating mechanisms causing toxicity, cell death, and disease [7, 8]. Bearing this in
mind, the simultaneously generated sister peptides of Aβ deserve a major focus, namely the
amino-terminal fragment (N-APP286) derived from sAPPβ as a ligand for the death receptor
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6 (DR6) [9], and the APP intracellular domain as created by the ε-cut of γ-secretase during the
RIP process [3], which is the topic of this paper. We will start by getting the architecture of
APP into place.
2. Architecture of the APP protein
APP can be divided into three domains (Figure 1). As a single pass type I membrane protein,
the N-terminal ectodomain of APP (residues 18 to 624 neglecting the signal peptide, numbers
refer to the neuronal splice form APP695, UniPROT entry: P05067-4) locates to the extracellular
space. The single hydrophobic transmembrane domain (TMD, residues 625 to 648) is followed
by the rather short APP intracellular domain (AICD, residues 649 to 695). More important than
this topological classification is the distinction according to the fragments produced by
secretase cleavage events [10]. The products produced by ectodomain shedding are sAPPα
(residues 18 to 612; cleaved by α-secretases, members of the ADAM family of zinc metallo‐
proteases) and sAPPβ (residues 18 to 596; cleaved by β-secretase, an aspartic protease also
known as BACE1 in the nervous system and BACE in peripheral tissue). The C-terminal
fragments (CTFs) generated by ectodomain shedding are the still membrane embedded αCTF
(CTF83) and βCTF (CTF99), respectively. The CTFs are subsequently cut in the RIP process by
the intramembrane aspartate protease presenilin (1 or 2) as part of the γ-secretase complex,
with αCTF being split into the p3 peptide and the AICD (residues 646 to 695) and βCTF into
the Aβ peptide (Aβ40: residues 597 to 636; Aβ42: residues 597 to 638) and again the AICD.
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Figure 1. Architecture of APP and of its proteolytic fragments. A. Domain architecture of the neuronal splice var‐
iant APP695. Domains with known atomic structures (E1 and E2) and the TMD are shown as ribbon diagrams in a col‐
our code from blue (N-terminus) to red (C-terminus). Dashed lines give structurally unknown regions. Proposed
homodimeric interactions within E1 and E2 are shown in gray. Positions of secretase cleavage events and the respec‐
tive breakdown products are labeled. B. Sequence and proteolytic fragments within βCTF. Aβ peptides, the TMD
(gray), and sequence fingerprints within the AICD are colour coded.
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In terms of three-dimensional structure, only substructures within the large APP ectodo‐
main have been solved as independently folded subdomains. The N-terminal E1 domain
is  a  two-lobe  structure  consisting  of  the  growth  factor  like  domain  (GFLD,  residues
18-123)  and  a  copper-binding  domain  (CuBD,  residues  124  to  189),  both  comprising
mixed αβ topologies  rigidified  by  disulfide  bridges  [11-13].  The  E1  domain is  followed
by a highly acidic,  and probably unfolded,  stretch of  about 100 residues that  passes on
to the E2 domain (residues 290 to 495),  consisting of two coiled-coils connected through
a continuous central helix and resembling a spectrin family fold [14]. E1 and E2 domains
have been implicated in APP dimerization [14-16],  which is  reported to be modified by
the extracellular matrix [17],  and to have significant impact on localization and cleavage
events. In addition, dimerization might also involve the TMD region [16]. Besides dimeri‐
zation, APP architecture (and likely function) is also influenced by a series of post-trans‐
lational  modifications,  mainly  by  N-  and  O-glycosylation  and  phosphorylation  [18],
which  will  be  discussed  in  detail  below.  The  reminder  of  the  ectodomain  between  E2
and the TMD, the so-called juxtamembrane region (residues 496 to 624), is again intrinsi‐
cally disordered based on secondary structure prediction and contains the cleavage sites
for  the  α-  and  β-secretases.  The  single  TMD  is  clearly  α  helical,  although  with  partial
propensity  in  forming β  structures.  This  propensity  extends  also  to  the  juxtamembrane
region with the fatal consequence, that after secretase cleavage the amyloid peptide folds
into  a  β  hairpin  structure  and  aggregates  to  form  the  toxic  oligomers  and  finally  the
amyloid  fibrils.  Finally,  the  AICD  itself  is  again  intrinsically  disordered  as  shown  by
NMR and CD experiments [19, 20]. Importantly however, this small C-terminal stub has
recently  been  shown  to  adopt  different  conformations  reflecting  its  versatile  functions.
The structure-function relationship of the AICD shall be described in the following.
3. Biology of the AICD: Tales of a tail
When  talking  about  the  AICD,  a  clear  distinction  has  to  be  made:  the  function  (and
probably also the structure)  is  different  for  AICD as part  of  APP at  the membrane and
for AICD as peptide generated by ε-cleavage of γ-secretase and first described by Passer
et al. [21]. Within the AICD three sequence motifs have been identified to be of function‐
al relevance. The first one is the 653YTSI sequence, which has been implicated in the baso‐
lateral  sorting  of  APP  in  polarized  MDCK  cells  [22]  and  which  is  reminiscent  to  the
YXXΦ (X: any residue; Φ: aromatic or large hydrophobic residue) consensus motif as ty‐
rosine-based and clathrin-mediated endocytic sorting signal [23]. Indeed, when Tyr653 is
mutated to  alanine,  APP is  equally  distributed on apical  and basolateral  membranes  in
MDCK cells [24].  Somewhat surprisingly,  in neurons polarized sorting occurs independ‐
ently  of  this  signal  [25].  Subcellular  trafficking and neuronal  APP sorting is  still  poorly
understood  [26]  and  remains  a  topic  of  intense  investigation.  This  first  motif  contains
three phosphorylatable residues (YTS), and it has been reported that at least Thr654 and
Ser655 are phosphorylated in the adult rat brain under physiological conditions [27].
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Much more attention has been drawn to the second fingerprint 667VTPEER, as this site seems
to be also critically involved in pathophysiological processes. While the function of the residues
has remained elusive prior to the availability of structural data, Thr668 has since been
established as the major phosphorylation site of APP and its physiological function has been
investigated in the adult rat brain, post mitotic differentiating neurons and dividing cells [18].
Whereas pT668 in neurons is dominant in the fully-glycosylated mature APP, in differentiating
cells the purely N-glycosylated immature protein as present in the endoplasmic reticulum and
the early Golgi is of relevance. Accordingly, different kinases are responsible for Thr668
phosphorylation. In neurons, it is glycogen synthase kinase-3β (GSK3β) and cyclin-dependent
kinase 5 (Cdk5), while Cdk1 and cdc2 kinase phosphorylate this residue in dividing cells.
Moreover, when cells are exposed to stress, phosphorylation is taken over by c-Jun N-terminal
kinase (JNK) [28].
Phosphorylation on Thr668 of APP depends on the presence of Pro669 and strongly affects
Aβ production [29]. This is reminiscent of the Tau protein, where the phosphorylation of
certain serine and threonine residues depends on adjacent proline residues and leads to tangle
formation [29]. A first molecular explanation for the proline-dependency was revealed by
studies showing that the prolyl isomerase Pin1, catalyzing the cis-trans isomerization of the
Thr-Pro peptide bond, increases amyloidogenic APP processing and selectively elevates Aβ42
levels. Intriguingly, Pin1 is down regulated and/or inhibited by oxidation in neurons of
Alzheimer's disease patients and Pin1 knockout causes neurodegeneration (and tauopathy).
Pin1 binds to Thr668-phosphorylated APP and accelerates Pro669 isomerization (by a factor
of 103). Thus, the AICD swaps between two conformations, as visualized by NMR [29]. This
conformational switch may in turn have crucial consequences with regard to the AICD protein
interacting network, as shown for the neuronal adaptor protein Fe65 (Figure 2 and see below)
[20, 30]. To evaluate in as much the phosphorylation state of Thr688 controls APP processing
in vivo, knockin mice were generated in which Thr668 was changed to alanine (APPTA/TA) [31,
32]. The APPTA/TA mutation, and thus absence of phosphorylation, did not significantly alter
APP localization, processing, and Aβ generation, thus questioning the in vivo role of Thr668
phosphorylation. However, these studies cannot rule out the possibility that a pathological
increase in Thr668 phosphorylation, as found in AD patients [33], will also modulate its
function. In line with this notion, Thr668 phosphorylation has also been reported to influence
APP cleavage by caspases between residues Asp664 and Ala665, producing the cytotoxic
AICD-C31 fragment, a process that has been strongly implicated in AD pathogenesis [34].
The third and most intensely studied fingerprint within the AICD is the 681GYENPTY sequence
containing an NPXY motif, a well-established internalization signal for membrane proteins
[35]. NPXY is a classical tyrosine-based sorting signal for transmembrane proteins to endo‐
somes and lysosomes [23]. However, the signal has been shown to only mediate rapid
internalization of a subset of type I membrane proteins, including APP as well as members of
the low-density lipoprotein (LDL) receptor family and integrin β. These proteins are internal‐
ized via clathrin-coated pits. Nevertheless evidence for a direct interaction of NPXY motifs
with the coat or the AP-2 adaptor is weak.
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Figure 2. AICD in health and disease. Different fates of the AICD are exemplified for the main AICD interaction with
Fe65-PTB2 (red T-box: TPEE, cyan Y-box: NPTY, G: glycine hinge, gray cylinder: C-terminal helix of Fe65-PTB2). In the
non-phosphorylated state, AICD forms a stable complex with Fe65-PTB2 that assembles in ternary complexes with i.e.
Tip60 or CP2/LSF/LBP1 via Fe65-PTB1. Upon cleavage by the secretases, the liberated complexes are involved in tran‐
scription activation. Alternatively, caspase cleavage within the AICD results in cytotoxic AICD-C31, which might com‐
pete with AICD for Fe65-PTB2 binding and induce apoptosis. Phosphorylation of either Thr668 (I.) or Tyr682 (II.) results
in a destabilization of the Fe65-PTB2/AICD interaction (shown in brackets) and results in complex dissociation. Phos‐
phorylation stimulates (I.) neuronal differentiation or (II.) initiates signaling cascades. Deregulation of the Fe65-PTB2/
AICD interactions is strongly implicated in Alzheimer’s disease progression.
Instead, the NPXY motif is well known to interact with adaptor proteins containing a domain
known as phosphotyrosine-binding (PTB) or phosphotyrosine-interacting domain (PID) [36].
PTB domains reveal a fine tuned plasticity in ligand recognition, and besides recognizing
phosphorylated NPXpY motifs, most PTB adaptor proteins can also bind to their ligand in a
pY-independent manner. Accordingly, in vitro phosphorylation of Tyr687, which does not
seem to occur in the brain [18], does i.e. not alter the binding affinity of AICD to its major PTB-
containing adaptor protein Fe65.
In APP, the NPXY signal is extended by three residues at the N-terminal side (GYE), with
especially Tyr682 being most critical for function [31, 37, 38]. The motif is present in many
lysosomal glycoproteins that are endocytosed and targeted to the lysosomes [39]. In cell-
culture studies, Tyr682 can be readily phosphorylated by the nerve growth factor receptor
TrkA and the tyrosine kinases Abl and Src [40]. In brains of AD patients, it is known that at
least βCTF is phosphorylated, whereas this is not the case for αCTF [41]. In addition, phos‐
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phorylation regulates both AICD peptide formation and AICD-dependent cellular responses
(Figure 2). These data point to a sorting function regulated by Tyr682 phosphorylation, with
non-phosphorylated APP kept at the plasma membrane and therefore processed by α-
secretase, and a phosphorylation-dependent re-localization resulting in β-cleavage. Sorting
implies docking to respective intracellular trafficking machineries and their adaptors, includ‐
ing PTB domain containing proteins. Consistently, an APPYG/YG mutation introduced into the
endogenous APP locus by knock-in led to a marked shift toward the non-amyloidogenic
pathway in brain with increased levels of full length APP, sAPPα, αCTF, unaltered βCTF and
reduced sAPPβ and Aβ40 levels [31].
Sorting due to differentially phosphorylated residues is one side of the medal,  signaling
is the other [40]. Two signaling proteins are well known to require Tyr682 phosphoryla‐
tion for binding to APP-CTFs, namely ShcA and Grb2. ShcA is a member of a family of
cytoplasmic adaptor proteins (ShcA, ShcB, ShcC) that interacts with its  PTB and Src ho‐
mology2 (SH2) domains with receptor tyrosine kinases (RTKs) and activated growth fac‐
tor  receptors,  which  is  the  case  also  for  SH2/SH3  domains  containing  Grb2  [42].  The
initiated  cascades  are  involved  both  in  cell  proliferation  and  gene  transcription  events,
like i.e.  the MAP kinase pathway.  Again,  binding occurs only to pTyr682 of  βCTFs but
not  of  αCTFs [41]  (Figure  2).  Whereas  the  reasons for  the  different  binding preferences
remain  elusive,  the  underlying  structural  transitions  within  the  AICD itself  modulating
sorting and signaling have been studied in some detail.
4. Structural transitions within the AICD
First structural insights on the AICD peptide came from NMR experiments, revealing most of
the AICD to be unstructured. The transient structure (also termed intrinsic disorder: ID) of
cytoplasmic domains of membrane proteins is well suited for the molecular recognition in
intracellular signaling events for a number of reasons [43]: (i) modulation of the structural
propensity provides ID proteins with the capability to combine high specificity with low
affinity; (ii) binding diversity in which one region specifically recognizes differently shaped
partners by structural accommodation at the binding interface, a phenomenon known as one-
to-many signaling; (iii) binding commonality in which distinct sequences recognize a common
binding site (with eventually different folds); (iv) the formation of large interaction surfaces
as the ID region wraps up or surrounds its binding partner, making it possible to overcome
steric restrictions; (v) faster rates of association by reducing dependence on orientation factors
and by enlarging target sizes; (vi) faster rates of dissociation by unzipping mechanisms; (vii)
the precise control and simple regulation of the binding thermodynamics; and (viii) the
reduced life-time of ID proteins in the cell, possibly representing a mechanism of rapid
turnover of important regulatory molecules. A prominent example of intrinsically disordered
proteins is α-synuclein, a protein critically involved in Parkinson’s disease, which binds to a
multitude of partners differentially by alternative folding [44], a feature that equally applies
to the intracellular domain of APP.
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Although NMR experiments revealed the AICD to be intrinsically disordered, the TPEE and
NPTY motifs where found to form type I β-turns and TPEE forms part of a helix-capping box
[19] (Figure 3). Type I turns are the most frequent reverse turns in protein structures, which in
total involve about 1/3rd of all residues. Turns usually occur on the exposed protein surfaces
and represent molecular recognition sites. In a capping box, the side chain of the first helical
residue forms a hydrogen bond with the backbone of the fourth helical residue and, recipro‐
cally, the side chain of the fourth residue forms a hydrogen bond with the backbone of the first
residue [45]. These boxes are known to stabilize the N-termini of α-helices, and preordering
of the elements is thought to guide recognition of the intracellular protein network and to
reduce the entropic costs for complex formation, a feature that applies as well for APP. In
addition, the conformation of the TPEE motif and the propensity of forming the N-terminally
capped α helix critically depend on the phosphorylation status of Thr668 [20, 46]. This
structure-function relationship can be explored by the study of the AICD with its cytoplasmic
interaction partners.
Figure 3. The TPEE and NPTY motifs. A. The TPEE motif forms a type I β-turn and a helix capping box with two char‐
acteristic hydrogen bonds (dashed yellow lines). B. The NPTY motif forms a similar type I β-turn.
5. Interaction partners of the AICD
More than 20 proteins have been reported to interact with the AICD [47] (Table 1). However,
little is known whether these complexes occur also in vivo and what relevance they may have
for cell physiology or AD pathogenesis. Basically, they can be classified in modifying, sorting,
or signaling interactions. The modifying enzymes have been already mentioned and account
for phosphorylation and prolyl cis/trans isomerization events. Basolateral sorting is guided by
the protein PAT1, which is the only protein that has been shown to directly interact with the
653YTSI motif and is associated with microtubules [48].
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Knowledge about the interaction partners for the 667VTPEER motif is similar scarce. Major
binder for the motif, and as well for the complete AICD, are the multi-domain adaptor/
scaffolding proteins of the Fe65 family (Fe65, Fe65L1, and Fe65L2) [49]. The only additional
binding partner to the 667VTPEER motif is the dimeric adaptor protein 14-3-3γ, which seems
to stabilize the AICD/Fe65 interaction [50]. Fe65 is enriched in brain, whereas Fe65L1 and
Fe65L2 are more widely expressed. All three members contain a WW domain and two PTB
domains (PTB1 and PTB2). Through the PTB2 domain, they interact with the AICD and can
alter APP processing. After proteolytic processing of APP and release of the AICD to the
cytoplasm, Fe65 can translocate to the nucleus to participate in gene transcription events
(Figure 2), which is modulated by 14-3-3γ. This role is further mediated by interactions of Fe65-
PTB1 with the transcription factors CP2/LSF/LBP1 [51] and Tip60 [52] and the WW domain
with the nucleosome assembly factor SET [53]. Possible target genes identified by reporter
assays include GSK3β, Neprilysin, KAI1, and the low-density lipoprotein receptor-related
protein 1 (LRP1), but the physiological relevance for endogenous transcriptional regulation
has been discussed controversially [54]. Fe65-PTB1 also interacts with two cell surface
lipoproteins receptors, namely LRP1 [55] and ApoEr2 [56], forming trimeric complexes with
APP. The Fe55 WW domain further binds to mammalian Ena (mEna) [57], through which it
functions in regulation of the actin cytoskeleton, cell motility, and neuronal growth cone
formation [49]. The interaction has been implicated in a role for AICD signaling, in synaptic
plasticity and memory [58]. Moreover, Fe65 family proteins have attracted attention, as Fe65
or Fe65L1 double knockout mice revealed defects in cortical development with neuronal
mispositioning and ectopia, resembling human lissencephaly type 2 [59]. Interestingly, very
similar cortical defects were also found in APP-/-APLP1-/-APLP2-/- triple knockout mice
lacking all APP family members, suggesting a lack of APP/Fe65 dependent signaling as the
underlying cause of defects in both mouse mutants [60].
Fe65 binding to the AICD is unique, as its extended binding interface ranges from the
667VTPEER up to the 681GYENPTY motif and thus includes almost the entire AICD-C31
fragment (Figures 2 and 4A). Most other AICD interacting proteins recognize the 671GYENPTY
motif and neighbouring residues, with the interaction site spanning only about 10 residues.
As 681GYENPTY is essential for APP trafficking, the respective complexes can also alter APP
processing. Like Fe65, the binders for this motif are PTB-containing proteins including
members of the X11/Mint, JIP, Dab, and Shc families, as well as the Numb protein.
Mints consist of a divergent N-terminal region and conserved C-terminal sequences composed
of one PTB domain and two tandem PDZ domains. Although their regulatory role for APP
metabolism and transport is unresolved, it seems that they slow cellular APP processing and
reduce Aβ40 and Aβ42 secretion [61] by suppressing translocation of APP into BACE- and γ-
secretase-rich detergent-resistant membrane (DRM) domains, the so-called rafts [62, 66]. In
addition, there is evidence for a functional role of the AICD interaction with X11/Mints for
synapse formation [62, 67] and synaptic neurotransmitter release [68]. c-Jun N-terminal kinase
(JNK) interacting protein-1 (JIP1), a scaffolding protein for the JNK kinase cascade, has been
suggested to mediate anterograde transport of APP by the molecular motor kinesin-1.
However, this initial view has been challenged recently, as in contrast to this model, APP
Understanding Alzheimer's Disease10
constructs lacking the AICD are still transported to the nerve terminal by the fast axonal
transport mechanism [63].
Protein Interacting
domain
Interacting region
within AICD
Function Processing* Selected
citations
PAT1
Fe65,
Fe65L1, -L2
14-3-3-γ
X11/Mint
n.a.
PTB2
n.a.
PTB
YTSI
AICD-C31:
VTPEER + GYENPTY
VTPEER
GYENPTY
Basolateral sorting
Endocytosis, signaling and
transcription activation, ...
AICD/Fe65 stabilization
Exocytosis,
synapse formation, ...
α↑, β↓**
β↓
n.a.
β↓
[48]
[49]
[50]
[61] [62]
JIP1
Dab1
ShcA/Grb2
Numb
PTB
PTB
PTB/SH2
PTB
GYENPTY
GYENPTY
G(pY)ENPTY
GYENPTY
Transport
Transport, signaling
Signaling
Notch crosstalk
β↓
α↑, β↓
-
***
[63]
[64]
[42]
[65]
Table 1. Selected interaction partners of the AICD. *Data depend on cell line studied and are sometimes
conflicting. **Due to basolateral sorting and independent of PAT1 binding. Pat1 binding as such increases Aβ levels
[48]. ***Numb isoform dependent. ↓ denotes changes of non-amyloidogenic (α) or amyloidogenic (β) APP processing.
The Dab family member Dab1 regulates neuronal migration in mammals as an essential
component of the Reelin signaling pathway. Dab1 binds not only to APP family proteins [64]
but is well known to also bind to ApoE receptors (ApoEr2, VLDLR, and LRP) [69]. Dab1
increases cell surface expression of APP and ApoEr2, increases α-cleavage of APP and ApoEr2,
and decreases APP βCTF formation and Aβ production in transfected cells and in primary
neurons. The Dab family represents a prototype of PTB domains that bind their ligands in a
pY-independent manner [36]. In addition Dab proteins bind specifically to the phospho-
inositide (PI) PI-4,5-P2, which is predominantly located at the cellular membrane [70]. Binding
of PTB domains to PIs is a common principle to locate and orientate the adaptors at the target
membrane and to facilitate downstream events that accompany NPXY peptide binding. Since
PTB domains structurally belong to the pleckstrin homology (PH) superfold family and PH
domains are the prototypical PI binding domains, this function seems to be evolutionarily
conserved within PTB domains [36]. The crystal structures of ternary complexes of Dabs bound
to ApoEr2 [71] or APP [72] peptides and lipid revealed the lipid head group (IP3) to be
recognized by a large basic patch opposite the peptide-binding groove (Figure 4A). This patch,
also termed as “phospholipid binding-crown”, is conserved in many PTB domains [36].
Finally, binding of the AICD to the Numb PTB domain has been found to inhibit Notch
signaling [65], thereby establishing a crosstalk between the APP family and Notch in the
development of the peripheral nervous system (PNS) [73]. Like APP, the Notch receptor
undergoes a series of proteolytic cleavages that release the Notch intracellular domain (NICD)
that functions in transcriptional activation and subsequent signal transduction events,
including proliferation, differentiation, or apoptotic cues [74]. Similar to the NICD, the AICD
has been also found to regulate PI-mediated calcium signaling through a γ-secretase depend‐
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ent pathway [75, 76]. Cells lacking APP were shown to exhibit deficits in calcium storage that
could be reversed by transfection with APP constructs containing an intact AICD. Constructs
lacking the AICD were not able to rescue the phenotype, strongly indicating that this domain
is critically involved in endoplasmic reticulum (ER) calcium filling [76]. The multitude of
interactions with the AICD raises the question of the spatial and temporal regulation of all
these complexes, which needs a detailed structural analysis and a thorough biochemical
characterization.
6. Structure-function relationship of AICD complexes
The structure-function relationship of AICD complexes is governed by the one-to-many
principle with the intrinsically disordered AICD folding onto its manifold adaptor proteins,
in particular the PTB domain containing proteins. The recurrent interaction pattern includes
the recognition of the 681GYENPTY sequence, which shall be described in the following. High
resolution structures for this interaction are known for Dab1 and 2 [72], X11α [77], and the
Fe65-PTB2 domains [30] (Figure 4A). All PTB domains comprise a pleckstrin homology (PH)
fold consisting of a central β sandwich structure and a C-terminal α helix. Overall, complex
formation can be described as an induced-fit docking of the AICD to a rigid PTB domain
scaffold. Common to all the complexes is the binding of the 681GYEN sequence to the β5 strand
of the respective PTB domain by a mechanism called β completion, where a (antiparallel) β
sheet is created between two polypeptide chains (in trans) (Figure 4D). This interaction occurs
between the protein backbones and therefore strong sequence conservation is not present on
the PTB domain side. The conservation of AICD Gly681 is explained as longer side chains
would cause steric clashes with the PTB domains, as shown for the Fe65-PTB2/AICD interac‐
tion, where a G681A mutation abolishes the binding and Gal4-Tip60-dependent transactiva‐
tion [78]. The importance of the flexible glycine becomes evident when comparing the solved
PTB/AICD complexes (Figure 4B), revealing that Gly681 forms a hinge that allows for different
AICD conformations in the N-terminal direction. The hinge function correlates with a peptide-
flip of the glycine [30].
The side chain of Tyr682 is accommodated in the center of the interface and faces the C-termi‐
nal helix of PTB domains (Figures 3A and 3D). In all complexes it lays in a hydrophobic pocket,
however, the conformations between the Fe65-PTB2 and Dab1 in respect to X11α and Dab2
complexes are different. The hydrophobic nature of the pocket explains the general conserva‐
tion of a tyrosine or phenylalanine in this position in the context of NPXY sequences. All crys‐
tallized  complexes  are  specific  for  non-phosphorylated  Tyr682,  which  can  be  readily
explained, as there is no space available to accommodate the extra phosphate moiety. This is in
contrast to ShcA, where the binding site is more open [79], which apparently allows for binding
of a phosphorylated Tyr682 (although no structure of this complex is available). The readout of
the conserved glutamate is again different in the PTB complexes, although its function as selec‐
tivity filter seems to be minor. Whereas it forms i.e. a salt bridge with an arginine of X11α, in the
Fe65-PTB2 complex it is fixed in cis to Lys688 following the NPTY motif.
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Figure 4. Structure of the AICD in PTB domain complexes. A. Crystal structures of AICD peptides in complex with
PTB domains: Fe65-PTB2/AICD (PDB code 3DXC), X11α-PTB/AICD (1X11), and Dab1-PTB/AICD (1OQN). AICD peptides
are colour coded from blue (N-terminus) to red (C-terminus) and PTB domains are given in gray. In Fe65-PTB2/AICD,
the visible AICD structure corresponds to AICD-C31 and includes both the 667VTPEER and the 681GYENPTY sequences.
Dab1 is also bound to the polar head group of the lipid PI-4,5-P2 (IP3: inositol-1,4,5-triphosphate). B. Superposition of
the three AICD fragments as shown in Figure 3A (complex with Fe65-PTB2: red; X11α: blue; Dab1: green). The alterna‐
tive side chain conformations of Tyr682 are highlighted. C. Close-up view on the AICD helix αN in complex with Fe65-
PTB2. The 667VTPEER motif is highlighted in blue and hydrogen bonds within the capping box are given as dashed
lines. D. Interaction of the 680NGYE motif with Fe65-PTB2. The AICD stretch forms a β sheet in trans with strand β5 from
the PTB domain. The side chain of Tyr682 is accommodated in a hydrophobic pocket created by the C-terminal helix of
the PTB domain. E. Interaction of the 684NPTY motif and helix αC of the AICD with Fe65-PTB2. Tyr687 is rather solvent
exposed and helix αC is fixed to the PTB domain by hydrophobic interactions of two subsequent phenylalanines.
As already described, the 684NPTY sequence is forming a type I β-turn structure, which is
retained within the complexes and forms the N-terminal cap of an induced α-helix at the very
C-terminus of AICD (helix αC) (Figure 4E). Asn684 has a conserved structural role, with the
carboxamide of the side chain hydrogen bonding to the main chain of Thr686. As the carbox‐
amide is also tightly bonded to the PTB domains, the preformed NPTY conformation is a major
determinant and probably also a starting point for AICD folding and complex formation. The
conserved proline initiates and stabilizes the subsequent helix as found in many α helices. The
most prominent residue, however, is Tyr687, as the tyrosine at this position is the discriminator
for the classification in pY-dependent and pY-independent PTB domains [36]. In all structur‐
ally solved AICD/PTB domain complexes the peptide is non-phosphorylated, which reflects
the in vivo situation within neurons. The pY-independence is readily explained, as the binding
pocket is rather solvent exposed, and besides some van-der-Waals interactions of the benzene
ring the tyrosine is not coordinated further. The binding mode is quite different in pY-
Structure and Function of the APP Intracellular Domain in Health and Disease
http://dx.doi.org/10.5772/54543
13
dependent Shc or IRS1 peptide complexes, where the phosphate moiety is read out by a set of
conserved arginine residues and the binding pocket is much more pronounced [36].
The NPTY sequence is followed by the 688KFFEQMQN695 sequence, which forms the C-termi‐
nus of the AICD (Figures 4A and 4E). The conformation of this region is slightly different and
not always present in the structures, as the complexes have mostly been formed with truncated
synthetic peptides. In the Fe65-PTB2 (which contains the entire C-terminus) and X11α com‐
plexes, the region is part of the C-terminal helix αC. The helix is fixed to the PTB domains by hy‐
drophobic interactions of the two phenylalanines (Phe689 and Phe690) with the C-terminal
helices of the respective PTB domains. These helices are three turns longer than those of Shc
[79] and IRS1 [80] PTBs, and therefore the total interaction surfaces are significantly larger.
In most PTB domain complexes bound to an NPXY motif the described surfaces comprise the
entire interaction, however, there is a single exception to the rule: the Fe65-PTB2/AICD
complex, where the interface is about three times as large and includes an additional α helix
(helix αN, 669PEERHLSKMQQ679) N-terminal to the 681GYENPTY sequence (Figure 4C) [30].
This helix is N-terminally capped by the 667VTPEER motif comprising the phosphorylatable
Thr668 as already described. Like helix αC, helix αN is of amphipathic character and binds on
a hydrophobic patch on the Fe65-PTB2 surface located in between strand β5 and the N-
terminus of the C-terminal helix, which is almost perpendicularly crossed by helix αN.
Whereas Leu674 and Met677 cover the hydrophobic patch, Glu670, His673, and Gln678 are
involved in polar interactions with the PTB domain. With the exception of Glu670, the
667VTPEER capping box is not touching the PTB domain, which is somewhat astonishing, as it
was afore known that phosphorylation of Thr668 is detrimental to complex formation [20]. As
described for free AICD, the side chain of Thr668 is hydrogen-bonded to the main chain of
Glu671, and Pro668 is in trans configuration. Furthermore, the side chain of Glu671 is tied back
to the main chain nitrogen of Thr668, and thus completing the rigid helix cap.
The most important question arising from structural data is how phosphorylation is able to
regulate Fe65-PTB2/AICD complex formation in a process that is critically involved in Aβ gen‐
eration and AD pathogenesis? Phosphorylation induces a cis configuration of Pro669 [46],
which is incompatible with the formation of helix αN. As found by mutational studies [30], the
destruction of the helix cap increases the entropy of the system and reduces the binding affini‐
ty, and once the helix is dissolved, the remaining interfaces are not sufficient for maintaining
the complex. This molecular switch model is only valid for the Fe65-PTB2/AICD interaction, as
all other PTB domains do not contact Thr668 and phosphorylation does therefore not alter their
binding affinity [20].  Intriguingly,  the Fe65-PTB2/AICD interface spans almost the entire
AICD-C31 fragment, which has been implicated in apoptotic events. This raises the next ques‐
tion: what determines stability, lifetime, and eventually toxicity of the AICD?
7. AICD turnover
The turnover of APP is very fast (with a half life of cell surface APP of about 30-40 minutes
only [81] and only about 10% of APP are estimated to reach the cellular membrane, whereas
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the majority of APP locates to the Golgi apparatus and trans-Golgi network [10]. APP not shed
at the surface is internalized within minutes [82], delivered to endosomes, and if not degraded
in lysosomes recycled to the cell surface [83]. AICD is even more difficult to study, as due to
its small size it is rapidly degraded once it is released from the membrane by the insulin
degrading enzyme (IDE) [84], that also degrades the Aβ peptide, by the proteasome [85], or
by the endosomal/lysosomal system [86]. However, AICD found in the nucleus appears to be
more stable, suggesting that AICD involved in signal transduction escapes rapid degradation
[87]. Nuclear AICD is stabilized via interaction with Fe65 [88, 89], which accordingly has a
dominant function in AICD mediated physiological and pathophysiological processes.
From a structural viewpoint it is evident that the enlarged and unique protein-protein interface
coupled with high affinity binding prevents the AICD from degradation. Interestingly, AICD-
C31 (starting at Ala665), which is believed to induce apoptosis and is enriched in AD brains
[34], fits exactly in length with the AICD part interacting with Fe65-PTB2. Hence, two scenarios
comprising a modulating role for Fe65 in AICD-C31 mediated neurotoxicity might be envis‐
aged: (i), under physiological conditions Fe65 protects the AICD from caspase cleavage
occurring at Asp664 and might therefore inhibit apoptosis as shown previously [90] and (ii),
increased levels of AICD-C31 compete with AICD binding as part of full-length APP and
therefore interfere with physiological Fe65 functions including nuclear signaling and traffick‐
ing of APP. In any case, modifying the protein-interacting network around the AICD seems
to be a valid target for decreasing neurotoxicity and the treatment of AD.
8. Conclusion
Despite enormous efforts to develop an efficient treatment for AD, only symptomatic treat‐
ments with modest impact on the progress of the disease are available [6]. Drugs currently
approved for the treatment of AD are either acetylcholine esterase inhibitors to increase the
level of the neurotransmitter, which is depleted in AD brains, or antagonize the NMDA
receptor to prevent abnormal neuronal stimulation [91]. None of them directly targets the
amyloid cascade and would thereby allow for a disease-modifying treatment. Many current
therapeutic approaches for AD focus on the reduction of the Aβ load either by inhibiting the
involved secretases BACE and γ-secretase, or by augmenting the elimination of amyloid
peptides, e.g. by active or passive immunotherapy [6]. Finally, a smaller number of trials have
targeted ApoE4 levels or either tau phosphorylation or tau aggregation. None of the ap‐
proaches was successful so far, which means that either there were not enough clinical trials
or the ideas were too simplistic to be potent for a complex disease. Like for other complex
diseases (i.e. hypertension or AIDS), a combination of drugs that have different modes of action
could be the key to success.
In this  sense,  the AICD might  be re-evaluated as  a  potential  drug target.  In contrast  to
Aβ, the AICD is a physiological highly relevant protein domain modulating a diverse set
of  important APP functions including trafficking and signal  transduction.  As both proc‐
esses  are  also  directly  affecting  Aβ  production,  upstream  targeting  of  AICD  might  be
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beneficial  as  the  Aβ pathology  is  prevented  a  priori.  Moreover,  the  pathophysiology  of
the AICD and its breakdown product AICD-C31 has come into the focus of AD research
and would  be  tackled  directly.  As  the  AICD by  its  nature  is  created  intracellular,  effi‐
cient compounds need to be able to pass the plasma membrane and to accumulate with‐
in  neurons,  as  is  i.e.  the  case  for  the  NMDA  receptor  antagonist  memantine  [92].
However, the AICD is intrinsically disordered, and therefore the protein interaction net‐
work  around  the  AICD  might  be  the  crucial  target  rather  than  the  AICD  itself.  Major
binding partners are the PTB domains, with their known ability to modulate Aβ produc‐
tion  (like  Fe65,  ShcA,  and  X11α)  and  to  specifically  recognize  and  fold  the  AICD.  Al‐
though  protein-protein  interactions  are  notoriously  difficult  to  be  targeted,  the  urgent
need for  a  disease-modifying  and efficient  treatment  for  this  devastating  disease  seems
worth the trial.
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